EQRx Inc. (EQRX)
2.34
-0.05 (-2.09%)
Nov 08, 2023, 9:00 PM - Market open
-2.09% (1D)
| Bid | n/a |
| Market Cap | 1.14B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -83.79M |
| EPS (ttm) | -0.55 |
| PE Ratio (ttm) | -4.254545454545455 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 11,934,302 |
| Avg. Volume (20D) | 2,946,852 |
| Open | 2.39 |
| Previous Close | 2.39 |
| Day's Range | 2.32 - 2.42 |
| 52-Week Range | 1.58 - 4.75 |
| Beta | 0.63 |
About EQRX
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antib...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 3, 2021
Employees 362
Stock Exchange NASDAQ
Ticker Symbol EQRX
Website https://www.eqrx.com